A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease.
Saved in:
| Title: | A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease. |
|---|---|
| Authors: | Ren, Hong1 (AUTHOR), Zhang, Wei2,3 (AUTHOR), Ouyang, Yan1 (AUTHOR), Guo, Junhong3 (AUTHOR), Xu, Hong4 (AUTHOR), Ma, Jie5 (AUTHOR), Luo, Xiaoping6 (AUTHOR), Pan, Xiaoxia1 (AUTHOR), Yuan, Yun2 (AUTHOR), Shen, Qian4 (AUTHOR), Li, Bin7 (AUTHOR), Feng, Qiqi7 (AUTHOR), Liu, Shi7 (AUTHOR), Chen, Nan1 (AUTHOR) cnrj100@126.com |
| Source: | Orphanet Journal of Rare Diseases. 8/4/2025, Vol. 20 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
